Market revenue in 2024 | USD 723.7 million |
Market revenue in 2030 | USD 1,044.5 million |
Growth rate | 6.3% (CAGR from 2024 to 2030) |
Largest segment | Defibrillators |
Fastest growing segment | Defibrillators |
Historical data | 2018 - 2023 |
Base year | 2024 |
Forecast period | 2025 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Pacemakers, Defibrillators, Cardiac Resynchronization Therapy (CRT) |
Key market players worldwide | Stryker Corp, BIOTRONIK, SCHILLER, Medtronic PLC, Abbott Laboratories, Koninklijke Philips NV, ZOLL Medical Corporation, Boston Scientific Corp, LivaNova PLC, Progetti Medical |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to cardiac rhythm management devices market will help companies and investors design strategic landscapes.
Defibrillators was the largest segment with a revenue share of 45.82% in 2024. Horizon Databook has segmented the France cardiac rhythm management devices market based on pacemakers, defibrillators, cardiac resynchronization therapy (crt) covering the revenue growth of each sub-segment from 2018 to 2030.
France's healthcare system offers relatively good coverage for CRMs, incentivizing hospitals and healthcare providers to adopt new & innovative devices. This is anticipated to lead to increased demand and market growth. Moreover, the new product launches and approvals are expected to support market growth in the forecast years.
For instance, in January 2024, MicroPort Scientific Corporation announced the CE mark approvals for TALENTIA and ENERGYA. These devices monitor the heart rhythm and deliver electrical shocks, if necessary, to regulate abnormal heartbeats. Ablation procedures, particularly catheter ablation for cardiac arrhythmias such as Atrial Fibrillation (AF), are becoming common in France.
This trend is driven by the growing acceptance of catheter ablation as a safe and effective treatment option for arrhythmias, leading to increased demand for the devices used in these procedures. According to the Ministry of Solidarity and Health (Ministère de la Santé et de la Prévention), in France, around 40,000 to 50,000 individuals die annually due to SCA and lack of timely intervention.
Horizon Databook provides a detailed overview of country-level data and insights on the France cardiac rhythm management devices market, including forecasts for subscribers. This country databook contains high-level insights into France cardiac rhythm management devices market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account